Akari Therapeutics (NASDAQ:AKTX) Shares Gap Up to $2.16

Share on StockTwits

Akari Therapeutics PLC (NASDAQ:AKTX)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $1.68, but opened at $2.16. Akari Therapeutics shares last traded at $1.91, with a volume of 12,435 shares trading hands.

Separately, Zacks Investment Research upgraded shares of Akari Therapeutics from a “sell” rating to a “hold” rating and set a $2.00 target price on the stock in a report on Thursday, November 7th.

The firm has a market cap of $32.67 million, a PE ratio of -11.29 and a beta of -2.81. The company’s 50-day simple moving average is $1.84 and its two-hundred day simple moving average is $1.96.

Akari Therapeutics (NASDAQ:AKTX) last released its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). As a group, equities analysts predict that Akari Therapeutics PLC will post -1 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Akari Therapeutics stock. Virtu Financial LLC grew its stake in Akari Therapeutics PLC (NASDAQ:AKTX) by 185.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,124 shares of the biopharmaceutical company’s stock after buying an additional 20,232 shares during the quarter. Virtu Financial LLC owned approximately 0.20% of Akari Therapeutics worth $53,000 as of its most recent SEC filing. Institutional investors own 13.54% of the company’s stock.

About Akari Therapeutics (NASDAQ:AKTX)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome.

Featured Article: What Does a Sell-Side Analyst Rating Mean?

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.